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OBJECTIVES: The objective of this study is to analyze the relationship between
12-month renal function and costs in post-kidney transplant patients from the
Brazilian Public Health System (SUS) perspective. METHODS: Non-interventional,
multicenter, retrospectivemedical chart review of patients that underwent kidney
transplantation. Three years follow-up data on resource use and associated costs
from adults (age18 years-old at time of transplantation), single kidney only trans-
plants from Jan/2004 to Jan/2005 were collected from 7 transplant centers in Bra-
zilian hospitals. Data were censored on graft loss. Estimated glomerular filtration
rates (eGFR) at 12-month post-transplantation were calculated using the abbrevi-
ated Modification of Diet in Renal Disease equation and stratified according to the
National Kidney Foundation K/Kidney Disease Outcomes Quality Initiative renal
function categories. Costs were adjusted to year 2004 at an annual discount rate of
5% and converted to 2010 USD. Case mix group costing approach was used to
determine average cost per day of hospitalization, stratified by cause (surgical or
clinical complication) and type (general ward, ICU). RESULTS: 498 subjects were
eligible for the analysis. Outpatient care resource use and associated costs (exclud-
ing costs with immunosuppressive therapy) did not significantly vary among pa-
tients in different eGFR categories, with average annual costs ranging from 664 and
921USD in the first year, 194 and 245USD in the second and 129 and 165USD in the
third year post-transplantation. However, a trend towards of increasing inpatient
costs (p0.001) and incidence of hospitalization per year with declining of renal
functionwas observed. After 3 years post-transplant, 41%of stage 1 Chronic Kidney
Disease (CKD) and 91% of stage 4 patients were re-admited to the hospital at least
once incurring an estimated average cost of 1,239 and 3,654USD, respectively.
CONCLUSIONS:Renal function,measured by 12-month post-transplant eGFR, is an
important determinant of costs of hospitalization in kidney graft recipients.
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OBJECTIVES: To quantify the cost-effectiveness of overactive bladder (OAB) treat-
ment with fesoterodine (FESO) relative to extended release tolterodine (TER) and
solifenancin (SOL) in Sweden based on recently-available data. METHODS: A 52-
week decision-tree model was developed using data from four 12-week, random-
ized clinical trials and published literature. Patients who did not achieve resolution
of urgency urinary incontinence (UUI) at week 4were titrated to higher doses in the
FESO and SOLmodel arms. TER is only available in one dose and all patients there-
fore remained on TER at week 4 regardless of UUI resolution. The published de-
crease in UUI episodes was used to estimate the proportion of UUI resolution with
SOL. Trial discontinuation data were fit to a Weibull survival model and extrapo-
lated to 52 weeks. Changes in health-related quality of life were assessed using
Overactive Bladder Questionnaire data from two of the trials andwere transformed
into preference-based utility values. Regression analysis determinedthe associa-
tion between trial utilities andmicturition/UUI episodes in order to estimate values
for SOL. Medical costs included antimuscarinic drugs, physician visits, laboratory
tests, incontinence pads and costs of OAB- or incontinence-related comorbidities.
Probabilistic sensitivity analysis was used to determine the impact of uncertainty
in the model inputs on its outcomes. RESULTS: 19.5%, 18.0%, and 16.3% of patients
receiving FESO, TER, and SOL, remained on treatment and were continent after 52
weeks. The respective quality-adjusted life years associated with FESO, TER, and
SOL,were 0.762, 0.756 and 0.752; overall costswere kr16,752, kr16,849, and kr17,047,
indicating that FESO is a lower-cost and more effective treatment option than TER
and SOL. Sensitivity analysis confirmed the superiority of FESO in over 80% of
model simulations. CONCLUSIONS: Results suggest FESO has lower costs and
higher efficacy and thus dominates both TER and SOL in treating OAB with UUI in
Sweden.
PUK12
COST-EFFECTIVENESS OF TOLTERODINE AS TREATMENT FOR OVERACTIVE
BLADDER (OAB) IN ADULT MEXICAN PATIENTS
Arreola-Ornelas H1, Rosado-Buzzo A2, Garcia-Mollinedo M2, Camacho-Cordero L2,
Muciño-Ortega E3, Mould-Quevedo JF4, Galindo-Suarez RM3
1Fundación Mexicana para la Salud AC, Mexico City, Mexico, 2Links & Links S.A, de C.V., Mexico
City, Mexico, 3Pfizer, Mexico City, Mexico, 4Pfizer, New York, NY, USA
OBJECTIVES:Worldwide prevalence of overactive bladder (OAB) is close to 10% in
adults. The urgent feeling to go to the toilet, frequency of voids and urinary incon-
tinence affects lifestyle and productivity of patients. The aim of this study was to
estimate the cost-effectiveness of tolterodine in the managing of OAB from an
institutional perspective.METHODS: A four-state Markovmodel was performed to
estimate health and economic consequences during a time horizon of one year
(one-month cycles). Effectiveness measures were mean percentage reduction in:
number of voids per day, number of urinary urgency events per day and number of
urinary incontinence events per day. Transition probabilities were obtained from a
meta-analysis employing international published literature. Comparators were
tolterodine (2 mg bid) and tablets of oxybutynin (5 mg tid) as reference treatment.
Resource use was obtained from the Instituto Mexicano del Seguro Social (IMSS)
databases (n377 cases). Costs were extracted from institutional (IMSS) official
sources. Costs included: visits to general practitioners and urologists, hospitaliza-
tion, drugs, medical procedures, laboratory tests, imagenology and adverse events
management. Probabilistic sensitivity analyses were performed employing boot-
strapping techniques. Acceptability curves were constructed. RESULTS: Tolterod-
ine and oxybutynin annual costs per patientwere: US$1,654.55 [95%CI US$1,486.97-
US$1,822.13] and US$1,537.38 [95%CI US$1,389.42-US$1,685.33], respectively
(p0.05). Tolterodine exhibits better outcomes than reference in all effectiveness
measures considered (p0.05). Incremental cost-effectiveness ratios for additional
percentage reduction of: number of voids, events of urinary urgency and events of
urinary incontinencewere: US$1,307.34 [95%CI US$1,268.73-US$1,345.96]; US$1,091.39
[95%CI US$1,059.15-US$1,123.62] and US$ 2,915.31 [95%CI US$2,829.14-US$3,001.42],
respectively. Acceptability curve showed that theprobability of tolterodine being cost-
effective is close tooneatawillingness topayofUS$3,170 (regardingpercent reduction
of number of voids). CONCLUSIONS: Tolterodine is more effective than oxybutynin
with similar treatment costs representing a more efficient alternative in the man-
agement of OAB at the IMSS.
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OBJECTIVES: To evaluate the cost-effectiveness of the early conversion of tacroli-
mus to mTOR inhibitors (mTORi) -sirolimus or everolimus- against continuous
treatment with tacrolimus in patients with renal transplantation in Colombia.
METHODS: A Markov model simulating patient’s natural history with renal trans-
plantation was constructed. The model was designed to predict the incidence of
rejection episodes, associated deaths, adverse events and graft loss. An individual-
level simulation was performed, generating 100,000 patients that started in the
reject’s free stage, using monthly cycles upon death or Colombian life-expectancy
(76 years). The model assessed several risk factors (creatinine levels, rejection ep-
isodes and diabetes) associate to graft loss. The transition probabilities were ex-
tracted from a systematic review of published literature. Direct medical costs were
gathered fromofficial databases (SISMED’s 2010 first semester and tariffsmanuals).
The third party payer’s perspective was used in the analysis. The effectiveness
measure usedwas: life - years gained (LYG). A 5 % discount rate was applied for the
costs and health outcomes. Cost-effectiveness ratio (CER) and incremental cost-
effectiveness ratio (ICER) were estimated. Lastly, deterministic and probabilistic
sensitivity analyses were also performed. RESULTS: Compared to tacrolimus,
sirolimus showed a favorable difference of 0.74 LYG (10.26 vs. 9.52); with a CER of
US$37,302 and US$39,731; respectively. In addition, ICER between the two men-
tioned alternatives resulted in US$6,130. For everolimus no published evidence of
efficacywas found for the evaluated scheme, therefore the effectiveness of everoli-
mus was assumed similar to sirolimus exhibiting an ICER of US$ 70.440 against
tacrolimus. Sensibility analyses modifying this last assumption showed themodel
results are robust. CONCLUSIONS: The study suggests that sirolimus strategy is
cost-effective in Colombia for patients with renal transplantation using the 3 GDP
per capita threshold as recommended by the World Health Organization.
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OBJECTIVES: Few published models comparing sacral nerve neuromodulation
(SNM) with intravesical botulinum toxin-A injections (BTX) for the treatment of
idiopathic overactive bladder (OAB) include comprehensive specifications of clini-
cal pathways and costs.We developed amodel that accurately captures the clinical
and economic realities of SNM and BTX therapies.METHODS: Our Markov model,
which takes the United States Medicare perspective, compares two cohorts of hy-
pothetical patients with idiopathic OAB refractory to conservative care: those ini-
tiatingwith SNM (InterStim®Therapy, Medtronic, Inc. Minneapolis, MN) and those
initiating with BTX (BOTOX®, Allergan, Irvine, CA). Both cohorts are similar and
equally likely to receive either therapy. The time horizon is the SNM neurostimu-
lator battery life (5.5 years). The model accounts for treatment success probabili-
ties, adverse events (AEs), and SNM-related adjustments based on clinical litera-
ture and expert clinical input. Quality-adjusted life-years (QALYs) for persistent
OAB and successful treatment come from National Overactive BLadder Evaluation
(NOBLE) study. Patients not responding successfully to initial therapy discontinue
or switch therapies (patients try each therapy once). Costs (manufacturer pricing
and 2010Medicare payment schedules) and benefits are discounted 3% per annum.
RESULTS: At two years, SNM was more costly ($20,240 vs. $17,069 per patient) and
more effective (1.60 vs. 1.56 QALYs per patient). SNM became less costly at 3 years.
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